Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this podcast episode, listen to Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, discuss their takeaways on new data presented at ASH 2020 in nonmalignant hematologic diseases, including studies on disorders of bleeding and clotting, hemoglobinopathies, and GVHD.
Hanny Al-Samkari, MD
Mark A. Schroeder, MD
Sujit Sheth, MD
Released: February 10, 2021

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:

  • Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study
  • Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITP
  • New data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B
  • An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-up
  • Primary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHD
  • Top-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHD
  • Phase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHD


Hanny Al-Samkari, MD
Department of Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Sujit Sheth, MD
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Mark A. Schroeder, MD
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bristol-Myers Squibb
Epizyme Inc.
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Dr. Corey S. Cutler shares his views on current and future graft-vs-host disease (GVHD) therapies in this commentary from Clinical Care Options (CCO)

Corey S. Cutler, MD, MPH, FRCPC Released: April 27, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Interactive online tool providing expert management recommendations for β-thalassemia from Clinical Care Options (CCO)

Jeanne Boudreaux, MD person default Stephanie A. Fritch Lilla, MD Janet L. Kwiatkowski, MD, MSCE Sujit Sheth, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: April 22, 2021 Expired: April 21, 2022

Danielle Friedman, MD, on adipose dysfunction, insulinopenia, obesity, and diabetes after irradiation in cancer survivors

Danielle N. Friedman, MD, MS Released: April 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.